In what scenario would you recommend the flipped nivo/ipi dosing (nivolumab 3 mg/kg and ipilimumab 1 mg/kg) for treatment of metastatic melanoma?

Reference: CheckMate-511

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How does the latency from the original melanoma diagnosis affect your approach to neoadjuvant therapy in a patient with clinically detectable stage III nodal recurrence?

For a patient with metastatic melanoma with small, asymptomatic brain mets what is your preferred systemic therapy?

Given the emerging benefit of neoadjuvant immune checkpoint inhibitors in selected patients with cutaneous melanoma, when should lymph node basin ultrasound or cross-sectional imaging (CT/PET) be considered prior to wide local excision (WLE) with or without sentinel lymph node biopsy (SLNB) in patients with clinically node-negative disease?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.